Evidence map›Paper›PMID 41349567›Full record

ReviewAnnual review of medicine2026

Oncogene Mutations: The Shared Antigen Vaccines That Work?

Rodrigo Paredes, S Daniel Haldar, Shubham Pant, Eileen M O'Reilly

Abstract readReview
In one paragraph

Review in Annual review of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rodrigo ParedesIcahn School of Medicine, Mount Sinai Morningside-West, New York, NY, USA.
S Daniel HaldarDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; email: spant@mdanderson.org.
Shubham PantDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; email: spant@mdanderson.org.
Eileen M O'ReillyGastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; email: oreillye@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Total Neoadjuvant Therapy (TNT) for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaP50CA257881 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christine A Iacobuzio-Donahue, Eileen Mary O'Reilly · 2022 to 2026
$14.3M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA257881
6 · The paper itself

Abstract

Cancer immunotherapy has advanced through immune checkpoint inhibitors and T cell therapies, yet challenges persist in overcoming immune evasion. Neoantigen-based vaccines have shown promise, particularly in tumors with high tumor mutation burden. However, logistical barriers and tumor heterogeneity limit their scalability. Shared oncogenic driver mutations (e.g.,

Indexed as

Antigens, NeoplasmCancer VaccinesNeoplasmsOncogenesHumansImmunotherapyMutationProto-Oncogene Proteins p21(ras)Antigens, NeoplasmCancer VaccinesKRAS protein, humanProto-Oncogene Proteins p21(ras)cancer vaccinesEGFR-targeted vaccinesIDH-targeted vaccinesKRAS-targeted vaccinesmutation-driven vaccinesoncogene-directed immunotherapyshared antigen vaccines

Identifiers

PMID41349567
PMCPMC13653047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.